LSTALisata Therapeutics Inc
LSTA
Lisata Therapeutics Inc8,906
Mkt Cap
$39.57MVolume
51,019.0052W High
$4.8952W Low
$1.81PE Ratio
-2.11LSTA Fundamentals
Price
$4.48Prev Close
$4.52Open
$4.5250D MA
$3.11Beta
0.72Avg. Volume
367,231.00EPS (Annual)
-$2.40P/B
2.26Rev/Employee
$38,461.54$6.54
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Feb. 11, 2026 Insiders may stand to...
PR Newswire·10d ago
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their...
PR Newswire·24d ago
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA...
PR Newswire·24d ago
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lisata Therapeutics, Inc. (NASDAQ: LSTA) to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable...
Business Wire·1mo ago
All-Cash Buyout Sparks Breakout Move in Biotech Name
Mergers and acquisitions continue to reshape the biotech landscape as larger and better-capitalized players look to secure promising clinical assets earlier in the development cycle. For small and microcap biotech companies, these deals often arrive suddenly, with premium valuations reflecting not just current data but the long-term strategic value of novel platforms and differentiated pipelines. When that happens, the market tends to respond quickly.Shares of Lisata Therapeutics, Inc. (NASDAQ: LSTA) are surging Wednesday after the company announced it has entered into a binding term sheet ...
AllPennyStocks.com·1mo ago
All-Cash Buyout Sparks Breakout Move in Biotech Name
Mergers and acquisitions continue to reshape the biotech landscape as larger and better-capitalized players look to secure promising clinical assets earlier in the development cycle. For small and microcap biotech companies, these deals often arrive suddenly, with premium valuations reflecting not just current data but the long-term strategic value of novel platforms and differentiated pipelines. When that happens, the market tends to respond quickly.Shares of Lisata Therapeutics, Inc. (NASDAQ: LSTA) are surging Wednesday after the company announced it has entered into a binding term sheet ...
AllPennyStocks.com·1mo ago
Why Is Lisata Therapeutics Stock Gaining Today?
Lisata Therapeutics shares surged premarket after Kuva Labs agreed to acquire the company for $4 per share in cash plus two milestone-based CVRs.read more...
Benzinga·1mo ago
Lisata Therapeutics Agrees To Be Acquired By Kuva Labs In $4/shr Cash Deal
(RTTNews) - Lisata Therapeutics, Inc. (LSTA), a clinical-stage pharmaceutical company, on Wednesday said the company has entered into a binding term sheet to be acquired by privately held Kuva Labs...
Nasdaq News: Markets·1mo ago
<
...
1
>